More and more novel agents, such as anti-CD30 monoclonal antibody, anti-CD52 monoclonal antibody, and small molecular inhibitors targeting Bruton tyrosine kinase (BTK), B-cell lymphoma-2 (BCL-2), phosphoinositide 3-kinase (PI3K), and even chimeric antigen receptor (CAR) T-cell immunotherapy have been used to treat malignant lymphoma in recent years. This evidence concerns the gene BTK and lymphoma.